Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
--- end of press release ---
- Dr. Barbara Lösch, Head of Technology & Innovation, spoke at a Seminar titled “Incorporating Modular Control into Cell Therapies through Receptors to Enhance Therapy Persistence & Safety”.
- Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene gave a presentation titled “Developing Effective Methods to Monitor, Track & Assess T-Cell Efficacy In Vivo & In Vitro”.
- “With our E2E Platform, we provide solutions for all of these key areas, with innovation at multiple sequential steps of the discovery and development process.
- With our unique set of technologies, we are well positioned to provide new, best-in-class differentiated TCR-T therapies for treatment of patients with solid tumors.”